MeSH term | MeSH ID | Detail |
---|---|---|
Urinary Incontinence | D014549 | 4 associated lipids |
Lead Poisoning | D007855 | 4 associated lipids |
Alcohol-Related Disorders | D019973 | 3 associated lipids |
Kakonein is a lipid of Polyketides (PK) class. Kakonein is associated with abnormalities such as Fatty Liver, Chronic liver disease, Morphologically altered structure, Hypertensive disease and Cardiovascular Diseases. The involved functions are known as protein expression, Extravasation, Liver damage, mRNA Expression and cell activation. Kakonein often locates in Body tissue, Hepatic, Microvilli, Cytoplasm and Membrane. The associated genes with Kakonein are TJP1 gene, CD14 gene, iberiotoxin, AT-Rich Interactive Domain-Containing Protein 1A and NKS1 gene. The related lipids are dehydrosoyasaponin I and Steroids. The related experimental models are Knock-out.
To understand associated biological information of SCHEMBL105486, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
SCHEMBL105486 is suspected in Chronic liver disease, Hypertensive disease, Cardiovascular Diseases, Myocardial Infarction, Cerebrovascular accident, Fatty Liver and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with SCHEMBL105486
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Knock-out are used in the study 'MATE2 mediates vacuolar sequestration of flavonoid glycosides and glycoside malonates in Medicago truncatula.' (Zhao J et al., 2011).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Lee JH et al. | The suppressive effect of puerarin on atopic dermatitis-like skin lesions through regulation of inflammatory mediators in vitro and in vivo. | 2018 | Biochem. Biophys. Res. Commun. | pmid:29524423 |
Chen G et al. | Puerarin attenuates angiotensin II-induced cardiac fibroblast proliferation via the promotion of catalase activity and the inhibition of hydrogen peroxide-dependent Rac-1 activation. | 2018 | Chin J Nat Med | pmid:29425589 |
Hu Y et al. | Puerarin inhibits non-small cell lung cancer cell growth via the induction of apoptosis. | 2018 | Oncol. Rep. | pmid:29393465 |
Zeng X et al. | Puerarin inhibits TRPM3/miR-204 to promote MC3T3-E1 cells proliferation, differentiation and mineralization. | 2018 | Phytother Res | pmid:29368357 |
Fu C et al. | Puerarin protects endothelial progenitor cells from damage of angiotensin II via activation of ERK1/2‑Nrf2 signaling pathway. | 2018 | Mol Med Rep | pmid:29359784 |
Li W et al. | Puerarin-loaded PEG-PE micelles with enhanced anti-apoptotic effect and better pharmacokinetic profile. | 2018 | Drug Deliv | pmid:29587545 |
Wang X et al. | Puerarin prevents LPS-induced acute lung injury via inhibiting inflammatory response. | 2018 | Microb. Pathog. | pmid:29571724 |
Guo BQ et al. | Puerarin reduces ischemia/reperfusion-induced myocardial injury in diabetic rats via upregulation of vascular endothelial growth factor A/angiotensin-1 and suppression of apoptosis. | 2018 | Mol Med Rep | pmid:29568939 |
Wang T et al. | Puerarin promotes MIN6 cell survival by reducing cellular reactive oxygen species. | 2018 | Mol Med Rep | pmid:29568901 |
Wu JY et al. | A microemulsion of puerarin-phospholipid complex for improving bioavailability: preparation, in vitro and in vivo evaluations. | 2018 | Drug Dev Ind Pharm | pmid:29513046 |